Trevi Therapeutics, Inc.

📍 New Haven, United States🗓 Founded 2011👥 26 employees💰 Last funded Dec 2012
Biotechnology Research🌐 trevitherapeutics.com
Website LinkedIn
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough. Trevi is headquartered in New Haven, CT.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2011
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Trevi Therapeutics, Inc. last raise funding?
The most recent investment in Trevi Therapeutics, Inc. recorded on gritt.io was in December 2012.
When was Trevi Therapeutics, Inc. founded?
Trevi Therapeutics, Inc. was founded in 2011.
What industry is Trevi Therapeutics, Inc. in?
Trevi Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Trevi Therapeutics, Inc. based?
Trevi Therapeutics, Inc. is headquartered in New Haven, United States.